Published by Unseen Progress, an independent publisher of caregiver research. Last reviewed 2026-05-10. Part of the Parkinson's caregiver research overview.
Short answer. Dyskinesia is the involuntary, writhing, dance-like movement that emerges as a side effect of long-term levodopa therapy in Parkinson's disease, typically after 5-10 years of treatment (Fahn et al., 2004; Olanow et al., 2000). It is fundamentally different from tremor and rigidity, and its appearance does not mean the disease is worsening — it means the brain's response to levodopa has changed. Management is a structured collaboration between the movement disorder specialist, the person, and the caregiver who watches the daily pattern (Bloem et al., 2021).
What dyskinesia is, and what it isn't
Dyskinesia in PD refers to involuntary movements that are not part of the underlying disease but are induced by the medication that treats it. The movements are typically choreiform — flowing, writhing, dance-like — and can affect the face, neck, trunk, arms, or legs. They are usually painless. They are almost always distressing to family members watching, and often less distressing to the person experiencing them than the off-period that would be the alternative (Marras et al., 2004).
The critical clinical distinctions:
- Dyskinesia is not tremor. Tremor in PD is rhythmic, typically 4-6 Hz, often worse at rest, and is a symptom of the disease. Dyskinesia is non-rhythmic, flowing, often more visible during activity, and is a side effect of the treatment.
- Dyskinesia is not rigidity. Rigidity is increased muscle tone, felt by an examiner. Dyskinesia is visible, involuntary motion.
- Dyskinesia is not "the disease getting worse." It signals that the brain's response to levodopa has narrowed — the therapeutic window between "too little" (off) and "too much" (dyskinetic) has shrunk. The disease may be progressing, but dyskinesia itself is a pharmacological event, not a disease event.
- Dyskinesia is not a reason to stop levodopa. Levodopa remains the most effective drug for PD motor symptoms across the entire course of the disease. The management goal is to reduce dyskinesia while preserving on-time, not to abandon the medication that produced it.
The patterns of dyskinesia
Movement disorder specialists distinguish three main patterns, each pointing to a different management strategy (Fahn et al., 2004):
- Peak-dose dyskinesia — the most common pattern, appearing 1-2 hours after a levodopa dose when plasma levels are highest. Often choreiform, affecting the limbs and trunk. Suggests the peak level is too high.
- Diphasic dyskinesia — appears as the levodopa level is rising or falling, with relief at peak. Often more dystonic (sustained postures) and frequently affects the legs. Less common, harder to manage.
- Off-period dystonia — sustained, often painful muscle contractions appearing when levodopa has worn off, classically early morning before the first dose. Technically a different phenomenon but often grouped with dyskinesia conversations.
A caregiver who can describe which pattern dominates — and when in the medication cycle the involuntary movements appear — gives the neurologist far more usable information than a description of "they're moving a lot."
Why dyskinesia develops
The mechanism is partly understood. In a healthy brain, dopamine signalling is tonic and stable. In Parkinson's, the surviving dopaminergic neurons cannot smooth the rising and falling plasma levodopa levels, so the brain experiences pulsatile dopamine — sharp peaks and troughs rather than steady tone. Over years, this pulsatile stimulation produces adaptive changes in striatal output pathways that lower the threshold for involuntary movement (Olanow et al., 2000; Schapira et al., 2009).
Risk factors that predict earlier dyskinesia onset include younger age at PD diagnosis, longer disease duration, higher cumulative levodopa dose, and certain genetic factors. None of these are reasons to delay levodopa when it is needed; the alternative — undertreating motor symptoms to delay dyskinesia — produces worse quality of life overall (Olanow et al., 2000).
How dyskinesia is managed
The management approach is iterative and almost always handled by a movement disorder specialist rather than a general neurologist, because the medication adjustments are subtle and the patterns are pattern-specific.
Adjusting the levodopa regimen
- Smaller, more frequent doses to lower the peak while preserving total daily exposure. The classic shift from three larger doses to five smaller ones.
- Extended-release formulations — Rytary, Sinemet CR, or specialised pumps — to flatten the plasma curve and reduce pulsatility.
- Adding a COMT inhibitor (entacapone, opicapone) to extend levodopa's half-life and reduce the depth of troughs without raising the peak.
- Adding an MAO-B inhibitor (rasagiline, safinamide) to provide background dopaminergic tone.
Adding amantadine
Amantadine is the only oral medication with consistent evidence for directly reducing dyskinesia rather than just adjusting levodopa exposure (Pahwa et al., 2015). The extended-release formulation (ADS-5102, Gocovri) is specifically FDA-approved for PD dyskinesia. Side effects include hallucinations, livedo reticularis, and ankle swelling, particularly in older patients.
Device-aided therapies
For people whose dyskinesia is severe and not adequately controlled by oral regimen adjustments, device-aided options exist:
- Deep brain stimulation (DBS) of the subthalamic nucleus or globus pallidus internus can dramatically reduce both off-time and dyskinesia, often allowing levodopa doses to be reduced by 30-50% (Krack et al., 2019). Best suited to mid-stage candidates with good levodopa response, no significant cognitive impairment, and clear motor fluctuations.
- Levodopa-carbidopa intestinal gel (Duodopa / Duopa) — continuous infusion via a PEG-J tube into the small intestine, producing very stable plasma levels and reducing both off-time and dyskinesia.
- Apomorphine subcutaneous infusion — a continuous dopaminergic delivery that can substitute for some of the oral levodopa burden.
Surgical lesioning
Where DBS is not appropriate, focused ultrasound thalamotomy and pallidotomy can be considered. These are less reversible than DBS but require no hardware.
What caregivers can usefully track
The American Academy of Neurology PD practice parameters and the MDS-UPDRS Part IV (Motor Complications) emphasise that medication adjustment for dyskinesia depends on accurate description of patterns. A caregiver's structured observation, even informally written down, beats a clinic-visit snapshot every time.
A useful log includes:
- Time each levodopa dose is taken.
- Time involuntary movements appear and how long they last.
- Whether the person was on, off, or transitioning when they appeared.
- Severity (mild — others notice; moderate — interferes with activity; severe — disabling).
- Body part(s) primarily affected.
- Whether the person was distressed by them or not.
Two weeks of this kind of log produces a pattern that distinguishes peak-dose from diphasic dyskinesia and points toward the right regimen adjustment.
What is not a problem to chase
- Mild peak-dose dyskinesia that the person is not bothered by. The trade-off is often more dyskinesia in exchange for more on-time, and many people prefer the dyskinetic on-period to the rigid off-period.
- Brief dyskinesia after a missed dose, when the person catches up. Transient.
- Increased movement during emotional activation, which can look similar but resolves.
What is worth raising urgently with the neurologist
- New severe dyskinesia in someone previously stable.
- Dyskinesia that becomes painful or causes falls.
- Sudden change in pattern (from peak-dose to diphasic, for instance).
- Dyskinesia accompanied by new psychiatric symptoms — impulse control disorder, hallucinations, severe mood swings — which can suggest dopaminergic side effects beyond the motor.
Related questions
References
- Fahn, S., Oakes, D., Shoulson, I., et al. (2004). Levodopa and the progression of Parkinson's disease. New England Journal of Medicine, 351(24), 2498-2508.
- Olanow, C. W., Watts, R. L., & Koller, W. C. (2000). An algorithm (decision tree) for the management of Parkinson's disease. Neurology, 56(11 Suppl 5), S1-S88.
- Schapira, A. H. V., Emre, M., Jenner, P., & Poewe, W. (2009). Levodopa in the treatment of Parkinson's disease. European Journal of Neurology, 16(9), 982-989.
- Pahwa, R., Tanner, C. M., Hauser, R. A., et al. (2015). Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Movement Disorders, 30(6), 788-795.
- Krack, P., Volkmann, J., Tinkhauser, G., & Deuschl, G. (2019). Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Movement Disorders, 34(12), 1795-1810.
- Marras, C., Lang, A. E., Krahn, M., et al. (2004). Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Movement Disorders, 19(1), 22-28.
- Goetz, C. G., et al. (2008). MDS-UPDRS. Movement Disorders, 23(15), 2129-2170.
- Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284-2303.
Additional reading: the Michael J. Fox Foundation dyskinesia resources; the Parkinson's Foundation motor complications materials; the International Parkinson and Movement Disorder Society clinical practice guidelines; the American Academy of Neurology PD practice parameters.
---
Unseen Progress publishes long-form caregiver research and builds research-backed daily trackers for the families covered. See the full Parkinson's caregiver research overview for the complete framework.